Efficacy of mexiletine in ventricular arrhythmias among patients in Taiwan: assessment by 24-hour Holter electrocardiography

Abstract

The effects of mexiletine in 30 patients with symptomatic recurrent ventricular arrhythmias were assessed by 24-hour Holter electrocardiography and M-mode echocardiography. The mean daily dose of mexiletine was 534 mg (range, 300 to 900 mg) and the interval of Holter follow-up was 16.9 days (range, 10 to 25 days). Total ventricular premature beats were reduced by 85% or more in 21 patients; in 19 of these patients there was a reduction of one or more modified Lown grades of ventricular arrhythmias. The overall reduction in Lown grades in the 30 patients was from 3.3 +/- 0.8 to 1.5 +/- 1.4 (P less than 0.0001). No significant changes in heart rate before or after mexiletine therapy were noted. Left ventricular echocardiography showed no significant changes in percentage fractional shortening after treatment. Adverse effects included gastrointestinal intolerance in seven patients and neurogenic symptoms in three. During the follow-up period of 1 to 11 (mean, 3.2) months, ventricular arrhythmias recurred in three patients. It is concluded that oral mexiletine is moderately effective and safe in controlling symptomatic recurrent ventricular arrhythmias.